erlotinib
美 
英
例句
A recent phase III trial of the combination of gemcitabine with erlotinib was associated with a significant prolongation of survival .
一项最新的III期试验显示吉西他滨联合厄罗替尼布可以显著延长生存期。
How erlotinib exhibits its antineoplastic activity in vivo needs to be further elucidated.
厄洛替尼在体内是如何发挥抗肿瘤活性的机制需要进一步阐释。
One patient of each cohort required dose reduction of erlotinib, both due to skin rash.
2组患者中均有1名患者因为皮疹需要减少厄罗替尼布剂量。
The addition of erlotinib to gemcitabine shows a small but significant improvement in overall survival (OS) versus gemcitabine alone.
与单独进行吉西他滨治疗相比较，增加补充厄洛单抗的治疗结果显示所有存活者（OS）可获得一个小的但是明显的改善。
Preliminary results of phase III trial in pancreatic cancer revealed an improvement in survival with the addition of erlotinib.
三期临床试验的初步结果揭示了加用厄洛替尼之后患者生存率的提高。
ObjectiveTo evaluate the efficacy, clinical benefits and toxicities of gemcitabine combined with erlotinib for advanced pancreatic cancer.
目的观察吉西他滨联合厄洛替尼方案治疗进展期胰腺癌的疗效、临床获益反应和毒性反应。
These findings provide evidence for the inhibitive activity of erlotinib in pancreatic cancer cells.
这些成果为厄洛替尼对胰腺癌细胞的抑制作用提供了证据。
Erlotinib is also being evaluated in combination with capecitabine in patients who failed first-line therapy with gemcitabine .
厄罗替尼布联合卡培他滨同样用于一线药物吉西他滨治疗失败的患者。
In vivo, erlotinib treated mice demonstrated a reduced tumor volume and weight as compared with control.
在体内，厄洛替尼对小鼠的治疗作用体现为与对照组相比肿瘤体积和重量的减小。
This study investigated the growth inhibitory effects of erlotinib in pancreatic cancer cells in vitro and in vivo.
本研究探寻了厄洛替尼在体内和体外对胰腺癌细胞生长的抑制效应。
The response rate to erlotinib therapy was similar in patients with tumor-only mutations and in those with tumor and serum mutations (67%).
对埃罗替尼治疗的反应率，仅在肿瘤组织中存在变异的患者和那些肿瘤和血浆中均存在变异的患者是相似的（67%）。
The maximum tolerated dose of erlotinib during the radiotherapy phase was 50 mg.
放射治疗期间厄罗替尼布的耐受剂量为50mg。
Grade 3 or greater elevations of AST were reported in 11 and 8% of patients receiving erlotinib and placebo, respectively.
应用厄罗替尼布和安慰剂组都有11（8%）名患者出现3级或更高的AST升高。
The molecularly targeted anticancer agent: New advances of erlotinib in the treatment of non- small cell lung cancer
分子靶抗癌药：埃洛替尼治疗非小细胞肺癌的新进展
Synergistic Inhibitory Effect of Indomethacin and Erlotinib on the Growth of Pancreatic Cancer Cells
吲哚美辛与埃罗替尼对胰腺癌细胞生长的协同抑制作用
Study evolution on molecular cancer-targeted drug of erlotinib
分子靶向抗癌药物埃洛替尼的研究进展
Study on chemotherapy of Erlotinib to non small cell lung cancer
埃洛替尼治疗非小细胞肺癌的研究
Death from acute interstitial lung disease related to erlotinib: 2 case reports
厄洛替尼引起急性间质性肺病死亡2例
